ArticleThe Journal of clinical endocrinology and metabolism2022
Correction to: "Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes".
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.